Search results for "bacteriophage therapy"

showing 4 items of 4 documents

Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of…

2021

Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

0301 basic medicineImipenemKlebsiella pneumoniaemedicine.drug_classMitomycin030106 microbiologyAntibioticsResistanceDrug repurposingMicrobial Sensitivity TestsBacteriophage therapybeta-LactamasesMicrobiologyPersistence03 medical and health sciencesMechanisms of Resistancemedicinepolycyclic compoundsHumansPharmacology (medical)BacteriophagesPathogenhealth care economics and organizationsPharmacologybiologyMitomycin CBroth microdilutionbiochemical phenomena metabolism and nutritionbiology.organism_classificationAntimicrobialhumanitiesAnti-Bacterial AgentsKlebsiella InfectionsSynergyImipenemKlebsiella pneumoniae030104 developmental biologyInfectious DiseasesLytic cyclemedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Outside-host phage therapy as a biological control against environmental infectious diseases

2018

Background Environmentally growing pathogens present an increasing threat for human health, wildlife and food production. Treating the hosts with antibiotics or parasitic bacteriophages fail to eliminate diseases that grow also in the outside-host environment. However, bacteriophages could be utilized to suppress the pathogen population sizes in the outside-host environment in order to prevent disease outbreaks. Here, we introduce a novel epidemiological model to assess how the phage infections of the bacterial pathogens affect epidemiological dynamics of the environmentally growing pathogens. We assess whether the phage therapy in the outside-host environment could be utilized as a biologi…

SI model0301 basic medicinevirusesmedicine.medical_treatmentVIBRIO-CHOLERAEDIVERSITYBacteriophageColumnaris diseasebacteriophageBacteriophageslcsh:QH301-705.5PathogenPOPULATION2. Zero hungerInfectivityeducation.field_of_studyPREDATIONEnvironmental opportunistCHANNEL CATFISHEVOLUTIONARY DYNAMICShost-parasite interactionflavobacteriumModeling and Simulationlcsh:R858-859.7biologinen torjuntaPhage therapy030106 microbiologyPopulationenvironmental opportunistVirulenceHealth InformaticsBiologylcsh:Computer applications to medicine. Medical informaticsinfektiotCommunicable DiseasesFlavobacteriumbakteriofagit03 medical and health sciencesmedicineAnimalsHumansPhage TherapyHost-parasite interactionBacteriophageeducationMORTALITYResearchFLAVOBACTERIUM-COLUMNAREOutbreakEnvironmental Exposurekalatauditbiology.organism_classificationVirologyfagiterapia030104 developmental biologylcsh:Biology (General)Infectious disease (medical specialty)BACTERIOPHAGE THERAPYVIRULENCE1182 Biochemistry cell and molecular biologyTheoretical Biology and Medical Modelling
researchProduct

Microencapsulation of Enteric Bacteriophages in a pH-Responsive Solid Oral Dosage Formulation Using a Scalable Membrane Emulsification Process

2019

A scalable low-shear membrane emulsification process was used to produce microencapsulated Escherichia coli-phages in a solid oral dosage form. Uniform pH-responsive composite microparticles (mean size ~100 &micro

maha-suolitulehduslcsh:RS1-441Pharmaceutical Sciencebacteriophage therapy<i>E. coli</i>ArticleDosage formbakteriofagitRSlaw.inventionlääkesuunnittelulcsh:Pharmacy and materia medica03 medical and health sciencesConfocal microscopylawEscherichiaenterobakteeritMembrane emulsification030304 developmental biology0303 health sciencesChromatographybiologykalvot (tekniikka)030306 microbiologyChemistryenteric infectionsE. colibiology.organism_classificationControlled releaseIn vitroQR3. Good healthfagiterapiamikrorakenteetpH-triggered releaseCell cultureGastric acidmicroencapsulationcontrolled releaseEudragit S100Pharmaceutics
researchProduct

Bacteriophage Adherence to Mucus Mediates Preventive Protection against Pathogenic Bacteria

2019

The mucosal surfaces of animals are habitat for microbes, including viruses. Bacteriophages—viruses that infect bacteria—were shown to be able to bind to mucus. This may result in a symbiotic relationship in which phages find bacterial hosts to infect, protecting the mucus-producing animal from bacterial infections in the process. Here, we studied phage binding on mucus and the effect of mucin on phage-bacterium interactions. The significance of our research is in showing that phage adhesion to mucus results in preventive protection against bacterial infections, which will serve as basis for the development of prophylactic phage therapy approaches. Besides, we also reveal that exposure to m…

medicine.medical_treatmentvirusesbacteriophage therapymedicine.disease_causebakteeritBacteriophageFish Diseaseshost-pathogen interactionslimakalvotPathogenOrganism1183 Plant biology microbiology virology11832 Microbiology and virology2. Zero hunger0303 health scienceshostpathogen interactionsbiologyvirulenssimucosal pathogensQR1-5023. Good healthBACTERIOPHAGEResearch ArticleProtein BindingbacteriophagesPhage therapyeducationvirusFlavobacteriumMicrobiologybakteriofagitHost-Microbe BiologyMicrobiologyViral Proteins03 medical and health sciencesImmunityVirologyAntibiosismedicineAnimalsPhage Therapy030304 developmental biologyMucous MembraneBacteria030306 microbiologybacterial virulenceMucinPathogenic bacteriaEditor's Pickkalatauditbiology.organism_classificationMucusfagiterapiaMucusFlavobacterium columnareBacteriamBio
researchProduct